Pharmaceutical company Galderma will be hosting a webinar in partnership with the Aesthetics journal this month.
The webinar will focus on clinical efficacy and safety of Abobotulinum toxin type A in powder and ready-to-use forms to help practitioners understand the use of both products in their practice.
The ‘Innovation Through Science: The Clinical Evidence of Galderma’s Neuromodulator Portfolio’ webinar will be led by aesthetic practitioners Dr Munir Somji and Dr Lara Watson.
Rene Wipperich, general manager at Galderma, commented, “We are very proud to have launched our new neuromodulator in March. Galderma will continue its commitment to bring new scientific solutions to our customers and drive innovation in the future.”
The webinar will be taking place on April 25 at 7:30pm GMT. Click here to register now.
